Please assess the completion status of the following clinical trial:

Trial Title: Inhaled Ciclesonide for Outpatients With COVID19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Symptomatic adult patients positive by PCR for COVID-19 within 5 days of enrollment with fever, cough, or shortness of breath. Provision of Informed Consent~At day 0, patients should be at home~Exclusion Criteria:~* Already on inhaled corticosteroid medication~* Currently using systemic steroids (oral or intravenous or intramuscular such as Prednisone) or use of steroids 7 days prior to enrolment~* Severely ill patients at enrollment (i.e., admitted to ICU at admission)~* Unable to self-administer the inhaler~* Known or suspected pregnancy and breastfeeding~* Known allergy to study medication or its components (non-medicinal ingredients; including lactose allergy (type I))~* Patients with untreated fungal, bacterial, or tubercular infections of the respiratory tract~* Current hospitalization~* Current use of oxygen at home or in the hospital

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ciclesonide inhaled and nasal (Type: ACTIVE_COMPARATOR): Intranasal ciclesonide BID 50mcg BID to each nostril and inhaled ciclesonide 600mcg BID x 14 days
- Placebo (Type: PLACEBO_COMPARATOR): Normal Saline intranasal BID and Placebo 3 puff MDI inhaled BID

Based on this trial design, predict the completion outcome and termination type (if applicable).